{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T12:08:05Z","timestamp":1750421285845},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00108-019-0615-6","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T14:23:11Z","timestamp":1557843791000},"page":"678-683","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Opportunistische Infektionen durch humane Herpesviren"],"prefix":"10.1007","volume":"60","author":[{"given":"N.","family":"Flo\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"615_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/ajt.14208","volume":"17","author":"JA Fishman","year":"2017","unstructured":"Fishman JA (2017) Infection in organ transplantation. Am J Transplant 17:856\u2013879","journal-title":"Am J Transplant"},{"key":"615_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10096-005-1286-x","volume":"24","author":"W Hellenbrand","year":"2005","unstructured":"Hellenbrand W, Thierfelder W, Muller-Pebody B et al (2005) Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997\u20131998. Eur J Clin Microbiol Infect Dis 24:131\u2013135","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"615_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/infdis\/163.5.1001","volume":"163","author":"S Kusne","year":"1991","unstructured":"Kusne S, Schwartz M, Breinig MK et\u00a0al (1991) Herpes simplex virus hepatitis after solid organ transplantation in adults. J\u00a0Infect Dis 163:1001\u20131007","journal-title":"J Infect Dis"},{"key":"615_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/JCM.01966-13","volume":"52","author":"NW Anderson","year":"2014","unstructured":"Anderson NW, Buchan BW, Ledeboer NA (2014) Light microscopy, culture, molecular, and serologic methods for detection of herpes simplex virus. J\u00a0Clin Microbiol 52:2\u20138","journal-title":"J Clin Microbiol"},{"key":"615_CR5","doi-asserted-by":"publisher","DOI":"10.1086\/522149","volume-title":"A model of Lytic, latent, and reactivating Varicella-zoster virus infections in isolated Enteric neurons","author":"AA Gershon","year":"2008","unstructured":"Gershon AA, Chen J, Gershon M (2008) A model of Lytic, latent, and reactivating Varicella-zoster virus infections in isolated Enteric neurons"},{"key":"615_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0304-3959(91)90124-G","volume":"44","author":"CPN Watson","year":"1991","unstructured":"Watson CPN, Deck JH, Morshead C et al (1991) Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 44:105\u2013117","journal-title":"Pain"},{"key":"615_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-2008-1041078","volume":"14","author":"KJ Elliott","year":"1994","unstructured":"Elliott KJ (1994) Taxonomy and mechanisms of neuropathic pain. Semin Neurol 14:195\u2013205","journal-title":"Semin Neurol"},{"key":"615_CR8","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/320169","volume":"32","author":"K Schmader","year":"2001","unstructured":"Schmader K (2001) Herpes zoster in older adults. Clin Infect Dis 32:1481\u20131486","journal-title":"Clin Infect Dis"},{"key":"615_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/166.5.1153","volume":"166","author":"SP Buchbinder","year":"1992","unstructured":"Buchbinder SP, Katz MH, Hessol NA et\u00a0al (1992) Herpes zoster and human immunodeficiency virus infection. J\u00a0Infect Dis 166:1153\u20131156","journal-title":"J Infect Dis"},{"key":"615_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q et\u00a0al (2014) Incidence of herpes zoster in patients with altered immune function. Infection 42:325\u2013334","journal-title":"Infection"},{"key":"615_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13063-016-1729-y","volume":"18","author":"M Rull\u00e1n","year":"2017","unstructured":"Rull\u00e1n M, Bulilete O, Leiva A et\u00a0al (2017) Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a\u00a0randomized controlled clinical trial. Trials 18:24","journal-title":"Trials"},{"key":"615_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ophtha.2007.10.009","volume":"115","author":"TJ Liesegang","year":"2008","unstructured":"Liesegang TJ (2008) Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 115:3\u201312","journal-title":"Ophthalmology"},{"key":"615_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/archpedi.1981.02130320013004","volume":"135","author":"G Fleisher","year":"1981","unstructured":"Fleisher G, Henry W, Mcsorley M et al (1981) Life-threatening complications of varicella. Am J Dis Child 135:896\u2013899","journal-title":"Am J Dis Child"},{"key":"615_CR14","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(00)05199-0","volume":"357","author":"MD De Jong","year":"2001","unstructured":"De Jong MD, Weel JF, Van Oers MH et\u00a0al (2001) Molecular diagnosis of visceral herpes zoster. Lancet 357:2101\u20132102","journal-title":"Lancet"},{"key":"615_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcv.2003.08.006","volume":"30","author":"R Stranska","year":"2004","unstructured":"Stranska R, Schuurman R, De Vos M et al (2004) Routine use of a\u00a0highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J\u00a0Clin Virol 30:39\u201344","journal-title":"J Clin Virol"},{"key":"615_CR16","first-page":"541","volume":"50","author":"RK-I","year":"2018","unstructured":"RK-I (2018) Mitteilung der St\u00e4ndigen Impfkommission (STIKO) beim RKIWissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epidemiol Bull 50:541\u2013566","journal-title":"Epidemiol Bull"},{"key":"615_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1098\/rstb.2000.0783","volume":"356","author":"DH Crawford","year":"2001","unstructured":"Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond, B, Biol Sci 356:461\u2013473","journal-title":"Philos Trans R Soc Lond, B, Biol Sci"},{"key":"615_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.med.46.1.381","volume":"46","author":"DW Hanto","year":"1995","unstructured":"Hanto DW (1995) Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 46:381\u2013394","journal-title":"Annu Rev Med"},{"key":"615_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/hon.791","volume":"24","author":"D Capello","year":"2006","unstructured":"Capello D, Cerri M, Muti G et al (2006) Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematol Oncol 24:212\u2013219","journal-title":"Hematol Oncol"},{"key":"615_CR20","volume-title":"Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction","author":"H-J Wagner","year":"2001","unstructured":"Wagner H\u2011J, Wessel M, Jabs W et al (2001) Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00103-003-0602-9","volume":"46","author":"G Enders","year":"2003","unstructured":"Enders G, B\u00e4der U, Bartelt U et al (2003) Zytomegalievirus- (CMV-) Durchseuchung und H\u00e4ufigkeit von CMV-Prim\u00e4rinfektionen bei schwangeren Frauen in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 46:426\u2013432","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"615_CR22","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM et al (2018) The third international consensus guidelines on the management of Cytomegalovirus in solid-organ transplantation. Transplantation 102:900\u2013931","journal-title":"Transplantation"},{"issue":"Suppl 7","key":"615_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/clinids\/12.Supplement_7.S727","volume":"12","author":"S Chou","year":"1990","unstructured":"Chou S (1990) Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 12(Suppl 7):727\u2013736","journal-title":"Rev Infect Dis"},{"key":"615_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1128\/AAC.49.3.873-883.2005","volume":"49","author":"C Gilbert","year":"2005","unstructured":"Gilbert C, Boivin G (2005) Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother (Bethesda) 49:873\u2013883","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"615_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/cid\/cis1035","volume":"56","author":"AK Le Page","year":"2013","unstructured":"Le Page AK, Jager MM, Iwasenko JM et\u00a0al (2013) Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 56:1018\u20131029","journal-title":"Clin Infect Dis"},{"key":"615_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","volume":"93","author":"O Witzke","year":"2012","unstructured":"Witzke O, Hauser IA, Bartels M et al (2012) Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1\u2011year results of a\u00a0randomized clinical trial. Transplantation 93:61\u201368","journal-title":"Transplantation"},{"key":"615_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/TP.0000000000002024","volume":"102","author":"O Witzke","year":"2018","unstructured":"Witzke O, Nitschke M, Bartels M et al (2018) Valganciclovir prophylaxis versus preemptive therapy in Cytomegalovirus-positive renal Allograft recipients: long-term results after 7 years of a\u00a0randomized clinical trial. Transplantation 102:876\u2013882","journal-title":"Transplantation"},{"key":"615_CR28","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF et al (2017) Letermovir prophylaxis for Cytomegalovirus in Hematopoietic-cell transplantation. N\u00a0Engl J Med 377:2433\u20132444","journal-title":"N Engl J Med"},{"key":"615_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","volume":"26","author":"LJ Bowman","year":"2017","unstructured":"Bowman LJ, Melaragno JI, Brennan DC (2017) Letermovir for the management of cytomegalovirus infection. Expert Opin Investig Drugs 26:235\u2013241","journal-title":"Expert Opin Investig Drugs"},{"key":"615_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.medmal.2016.09.004","volume":"47","author":"H Agut","year":"2017","unstructured":"Agut H, Bonnafous P, Gautheret-Dejean A (2017) Update on infections with human herpesviruses 6A, 6B, and 7. Med Mal Infect 47:83\u201391","journal-title":"Med Mal Infect"},{"key":"615_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fonc.2018.00512","volume":"8","author":"E Eliassen","year":"2018","unstructured":"Eliassen E, Lum E, Pritchett J et\u00a0al (2018) Human Herpesvirus 6 and malignancy: a review. Front Oncol 8:512","journal-title":"Front Oncol"},{"key":"615_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE et\u00a0al (2019) Kaposi sarcoma. Nat Rev Dis Primers 5:9","journal-title":"Nat Rev Dis Primers"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0615-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T23:17:18Z","timestamp":1589325438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0615-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0615-6","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"14 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Dolff hat Reiseunterst\u00fctzung bzw. Referentenhonorare von Astellas, Baxter, Correvio und Gilead erhalten. N.\u00a0Flo\u00df gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}